{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T02:04:49Z","timestamp":1768269889028,"version":"3.49.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,9,7]],"date-time":"2015-09-07T00:00:00Z","timestamp":1441584000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Negat Results BioMed"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12952-015-0034-8","type":"journal-article","created":{"date-parts":[[2015,9,7]],"date-time":"2015-09-07T16:13:53Z","timestamp":1441642433000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["A double-blind, randomised, placebo-controlled study of roxithromycin and doxycycline combination, roxithromycin alone, or matching placebo for 12\u00a0weeks in adults with frequent exacerbations of chronic obstructive pulmonary disease"],"prefix":"10.1186","volume":"14","author":[{"given":"Eskandarain","family":"Shafuddin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham D.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark D.","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillippa J.","family":"Poole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter R.","family":"Mullins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter N.","family":"Black","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,9,7]]},"reference":[{"key":"34_CR1","first-page":"245","volume":"4","author":"A Anzueto","year":"2009","unstructured":"Anzueto A, Leimer I, Kesten S. Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes. Int J Chron Obstruct Pulmon Dis. 2009;4:245\u201351.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"34_CR2","doi-asserted-by":"publisher","unstructured":"Staykova T, Black PN, Chacko EE, Poole P. Prophylactic antibiotic therapy for chronic bronchitis. Cochrane Database Syst Rev 2003(1):CD004105 doi: 10.1002\/14651858.CD004105 [published Online First: Epub Date].","DOI":"10.1002\/14651858.CD004105"},{"key":"34_CR3","doi-asserted-by":"publisher","first-page":"CD009764","DOI":"10.1002\/14651858.CD009764","volume":"11","author":"SC Herath","year":"2013","unstructured":"Herath SC, Poole P. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2013;11:CD009764. doi: 10.1002\/14651858.CD009764 . pub2[published Online First: Epub Date.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"34_CR4","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S2213-2600(14)70019-0","volume":"2","author":"S Uzun","year":"2014","unstructured":"Uzun S, Djamin RS, Kluytmans JA, Mulder PG, van't Veer NE, Ermens AA, et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2014;2(5):361\u20138. doi: 10.1016\/S2213-2600(14)70019-0 . published Online First: Epub Date.","journal-title":"Lancet Respir Med"},{"key":"34_CR5","doi-asserted-by":"publisher","unstructured":"Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA, Jr., Criner GJ, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689\u201398. doi: 10.1056\/NEJMoa1104623 . published Online First: Epub Date.","DOI":"10.1056\/NEJMoa1104623"},{"issue":"8","key":"34_CR6","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1136\/thorax.57.8.672","volume":"57","author":"F Blasi","year":"2002","unstructured":"Blasi F, Damato S, Cosentini R, Tarsia P, Raccanelli R, Centanni S, et al. Chlamydia pneumoniae and chronic bronchitis: association with severity and bacterial clearance following treatment. Thorax. 2002;57(8):672\u20136.","journal-title":"Thorax"},{"issue":"3 Pt 1","key":"34_CR7","doi-asserted-by":"publisher","first-page":"1148-51","DOI":"10.1164\/ajrccm.162.3.9912134","volume":"162","author":"L Wu","year":"2000","unstructured":"Wu L, Skinner SJ, Lambie N, Vuletic JC, Blasi F, Black PN. Immunohistochemical staining for Chlamydia pneumoniae is increased in lung tissue from subjects with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;162(3 Pt 1):1148-51. doi: 10.1164\/ajrccm.162.3.9912134 . published Online First: Epub Date.","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"34_CR8","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1136\/thorax.57.12.1087-a","volume":"57","author":"TA Seemungal","year":"2002","unstructured":"Seemungal TA, Wedzicha JA, MacCallum PK, Johnston SL, Lambert PA. Chlamydia pneumoniae and COPD exacerbation. Thorax. 2002;57(12):1087\u20138. author reply 88-9.","journal-title":"Thorax"},{"issue":"6","key":"34_CR9","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.ejim.2009.05.006","volume":"20","author":"GS Papaetis","year":"2009","unstructured":"Papaetis GS, Anastasakou E, Orphanidou D. Chlamydophila pneumoniae infection and COPD: more evidence for lack of evidence? Eur J Intern Med. 2009;20(6):579\u201385. doi: 10.1016\/j.ejim.2009.05.006 . published Online First: Epub Date.","journal-title":"Eur J Intern Med"},{"issue":"2 Pt 1","key":"34_CR10","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1164\/ajrccm.161.2.9904055","volume":"161","author":"DP Strachan","year":"2000","unstructured":"Strachan DP, Carrington D, Mendall M, Butland BK, Yarnell JW, Elwood P. Chlamydia pneumoniae serology, lung function decline, and treatment for respiratory disease. Am J Respir Crit Care Med. 2000;161(2 Pt 1):493\u20137.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"34_CR11","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1164\/ajrccm\/144.6.1408","volume":"144","author":"CD Beaty","year":"1991","unstructured":"Beaty CD, Grayston JT, Wang SP, Kuo CC, Reto CS, Martin TR. Chlamydia pneumoniae, strain TWAR, infection in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1991;144(6):1408\u201310. doi: 10.1164\/ajrccm\/144.6.1408 . published Online First: Epub Date.","journal-title":"Am Rev Respir Dis"},{"issue":"1","key":"34_CR12","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2165\/00151829-200403010-00007","volume":"3","author":"D Banerjee","year":"2004","unstructured":"Banerjee D, Honeybourne D, Khair OA. The effect of oral clarithromycin on bronchial airway inflammation in moderate-to-severe stable COPD: a randomized controlled trial. Treat Respir Med. 2004;3(1):59\u201365.","journal-title":"Treat Respir Med"},{"issue":"3","key":"34_CR13","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.pupt.2009.12.002","volume":"23","author":"F Blasi","year":"2010","unstructured":"Blasi F, Bonardi D, Aliberti S, Tarsia P, Confalonieri M, Amir O, et al. Long-term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy. Pulm Pharmacol Ther. 2010;23(3):200\u20137. doi: 10.1016\/j.pupt.2009.12.002 . published Online First: Epub Date.","journal-title":"Pulm Pharmacol Ther"},{"issue":"6","key":"34_CR14","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1159\/000321374","volume":"80","author":"ZY He","year":"2010","unstructured":"He ZY, Ou LM, Zhang JQ, Bai J, Liu GN, Li MH, et al. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration. 2010;80(6):445\u201352. doi: 10.1159\/000321374 . published Online First: Epub Date.","journal-title":"Respiration"},{"issue":"11","key":"34_CR15","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1164\/rccm.200801-145OC","volume":"17","author":"TA Seemungal","year":"2008","unstructured":"Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med. 2008;17(11):1139\u201347. doi: 10.1164\/rccm.200801-145OC . published Online First: Epub Date.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"34_CR16","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1378\/chest.120.3.730","volume":"120","author":"T Suzuki","year":"2001","unstructured":"Suzuki T, Yanai M, Yamaya M, Satoh-Nakagawa T, Sekizawa K, Ishida S, et al. Erythromycin and common cold in COPD. Chest. 2001;120(3):730\u20133.","journal-title":"Chest"},{"key":"34_CR17","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1465-9921-11-10","volume":"11","author":"S Sethi","year":"2010","unstructured":"Sethi S, Jones PW, Theron MS, Miravitlles M, Rubinstein E, Wedzicha JA, et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respiratory research. 2010;11:10. doi: 10.1186\/1465-9921-11-10 . published Online First: Epub Date.","journal-title":"Respiratory research"},{"key":"34_CR18","doi-asserted-by":"publisher","unstructured":"Evans DJ, Bara AI, Greenstone M. Prolonged antibiotics for purulent bronchiectasis. Cochrane Database Syst Rev. 2003(4):CD001392 doi: 10.1002\/14651858.CD001392 [published Online First: Epub Date].","DOI":"10.1002\/14651858.CD001392"},{"issue":"1","key":"34_CR19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1093\/jac\/dkh309","volume":"54","author":"MJ Schultz","year":"2004","unstructured":"Schultz MJ. Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis. J Antimicrob Chemother. 2004;54(1):21\u20138. doi: 10.1093\/jac\/dkh309 . published Online First: Epub Date.","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"34_CR20","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1001\/jama.2013.1937","volume":"309","author":"J Altenburg","year":"2013","unstructured":"Altenburg J, de Graaff CS, Stienstra Y, Sloos JH, van Haren EH, Koppers RJ, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA. 2013;309(12):1251\u20139. doi: 10.1001\/jama.2013.1937 . published Online First: Epub Date.","journal-title":"JAMA"},{"issue":"12","key":"34_CR21","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1001\/jama.2013.2290","volume":"309","author":"DJ Serisier","year":"2013","unstructured":"Serisier DJ, Martin ML, McGuckin MA, Lourie R, Chen AC, Brain B, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA. 2013;309(12):1260\u20137. doi: 10.1001\/jama.2013.2290 . published Online First: Epub Date.","journal-title":"JAMA"},{"issue":"9842","key":"34_CR22","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/S0140-6736(12)60953-2","volume":"380","author":"C Wong","year":"2012","unstructured":"Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):660\u20137. doi: 10.1016\/S0140-6736(12)60953-2 . published Online First: Epub Date.","journal-title":"Lancet"},{"key":"34_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2015-207194","author":"SE Brill","year":"2015","unstructured":"Brill SE, Law M, El-Emir E, Allinson JP, James P, Maddox V, et al. Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial. Thorax. 2015. doi: 10.1136\/thoraxjnl-2015-207194 . published Online First: Epub Date.","journal-title":"Thorax"},{"issue":"3","key":"34_CR24","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2147\/COPD.S681","volume":"3","author":"FJ Martinez","year":"2008","unstructured":"Martinez FJ, Curtis JL, Albert R. Role of macrolide therapy in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2008;3(3):331\u201350.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"20","key":"34_CR25","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1056\/NEJMoa1003833","volume":"366","author":"WA Ray","year":"2012","unstructured":"Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012;366(20):1881\u201390. doi: 10.1056\/NEJMoa1003833 . published Online First: Epub Date.","journal-title":"N Engl J Med"},{"issue":"1","key":"34_CR26","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1093\/clinids\/14.1.178","volume":"14","author":"MR Hammerschlag","year":"1992","unstructured":"Hammerschlag MR, Chirgwin K, Roblin PM, Gelling M, Dumornay W, Mandel L, et al. Persistent infection with Chlamydia pneumoniae following acute respiratory illness. Clin Infect Dis. 1992;14(1):178\u201382.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"34_CR27","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1128\/AAC.36.7.1573","volume":"36","author":"MR Hammerschlag","year":"1992","unstructured":"Hammerschlag MR, Qumei KK, Roblin PM. In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. Antimicrob Agents Chemother. 1992;36(7):1573\u20134.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"34_CR28","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/S0895-4356(96)00206-5","volume":"49","author":"DA Redelmeier","year":"1996","unstructured":"Redelmeier DA, Guyatt GH, Goldstein RS. Assessing the minimal important difference in symptoms: a comparison of two techniques. J Clin Epidemiol. 1996;49(11):1215\u20139.","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"34_CR29","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/0197-2456(89)90005-6","volume":"10","author":"R Jaeschke","year":"1989","unstructured":"Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10(4):407\u201315.","journal-title":"Control Clin Trials"}],"container-title":["Journal of Negative Results in BioMedicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12952-015-0034-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12952-015-0034-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12952-015-0034-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T19:05:30Z","timestamp":1498244730000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnrbm.biomedcentral.com\/articles\/10.1186\/s12952-015-0034-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,7]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["34"],"URL":"https:\/\/doi.org\/10.1186\/s12952-015-0034-8","relation":{},"ISSN":["1477-5751"],"issn-type":[{"value":"1477-5751","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,7]]},"article-number":"15"}}